Challenges for implementation The United Kingdom National External Quality Assessment Service (UKNEQAS) estimated that less than 10% of laboratories included non-HDL cholesterol in their reports; however, this was primarily due to lack of demand. Healthcare workers may need educating in what the non-HDL cholesterol test means, how to interpret the laboratory results, and how it compares with the previously used LDL cholesterol test. Support for implementation The Association of Clinical Biochemistry and Laboratory Medicine disseminated the updated guidance to their members specifically clinical scientists at the laboratories to request that they routinely include non-HDL cholesterol in their lipid profile reports. No additional equipment is needed for the non-HDL cholesterol test, other than a change to the software used when producing the report, and no extra time is needed to produce the lipid profile. Local organisations may wish to contact the laboratory they use to ensure it has this information. Lab Tests Online UK information on lipid profiling was updated to include details of the non-HDL cholesterol test. The information on this site explains what the test is, why it is carried out, what it involves and how to interpret the results. The website is a resource for both professionals and the public. Reduction of the primary prevention threshold from 20% to 10% CVD risk as calculated by QRISK2 Potential impact of implementation It is expected that there will be a reduction in the number of deaths and hospital-related admissions due to CVD events. Because the price of statins has fallen, using statins to reduce the risk of CVD at a lower threshold than NICE previously recommended is cost effective. Primary healthcare professionals may need to change their practice. 